Bio-Techne Corp has been making significant strides in the last quarter to position itself as a leader in the future of biotech. The company is set to release its Q3 2025 financial results, with market participants eagerly awaiting the disclosures. Bio-Techne has also announced dividends, suggesting a healthy financial outlook. A new
Customer Experience Centre has been inaugurated in Düsseldorf, Germany, further solidifying their stake in the European market. The company's debt to earnings ratio raised some concerns, but strong Q2 2025 results with remarkable revenue growth have appeased investors. The collaboration with Leica Biosystems and expansion of protease-free workflows show promising future developments. The firm has made a strategic investment in
Spear Bio, underlining its commitment to expanding its market footprint. There has been speculation around the company's financing, resulting in a temporary drop in stock value. However, the launch of revolutionary multiomics platforms and a new agreement with Waters Corporation indicate potential for recovery. Bio-Techne has also been downgraded by KeyBanc due to financing concerns. Despite this, the company continues to innovate with the release of GMP TcBuster Non-Viral Genome Engineering System and the commencement of the Early Access Program for Next-Generation Spatial Protein.
Bio-Techne Corp TECH News Analytics from Fri, 18 Nov 2022 08:00:00 GMT to Fri, 02 May 2025 11:54:37 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -2
